User profiles for Neil J Shah
 | Neil ShahAssistant Professor, Memorial Sloan Kettering Cancer Center Verified email at mskcc.org Cited by 884 |
[HTML][HTML] Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates
… J Clin Oncol … Shah … Interferon-alfa as a comparative treatment for clinical trials of
new therapies against advanced renal cell carcinoma J Clin Oncol 20289–2962002 [PubMed] …
new therapies against advanced renal cell carcinoma J Clin Oncol 20289–2962002 [PubMed] …
[HTML][HTML] Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
NJ Shah, G Al-Shbool, M Blackburn, M Cook… - … for immunotherapy of …, 2019 - Springer
Abstracts Background Patients with chronic viral infections including human immunodeficiency
virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing …
virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing …
[HTML][HTML] Salvage ipilimumab and nivolumab in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitors
A Gul, TF Stewart, CM Mantia, NJ Shah… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell
carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in …
carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in …
Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19
Importance Androgen deprivation therapy (ADT) has been theorized to decrease the severity
of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in …
of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in …
[HTML][HTML] Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer
WJ Kelly, NJ Shah, DS Subramaniam - Frontiers in oncology, 2018 - frontiersin.org
Lung cancer remains a leading cause of mortality with 1.69 million deaths worldwide. Activating
mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 deletions …
mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 deletions …
Product review on the Anti-PD-L1 antibody atezolizumab
Immunotherapy as a therapeutic strategy has seized the narrative throughout clinical
oncology over the past few years. Once considered a niche treatment for rare cancers, …
oncology over the past few years. Once considered a niche treatment for rare cancers, …
[HTML][HTML] Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
Background Pneumonitis related to immune checkpoint blockade is uncommon but can be
severe, fatal or chronic. Steroids are first-line treatment, however, some patients are refractory …
severe, fatal or chronic. Steroids are first-line treatment, however, some patients are refractory …
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: results of a phase 2 trial.
…, N Shapnik, D Tassone, C Dadoun, NJ Shah… - 2021 - ascopubs.org
4509 Background: Cabozantinib plus nivolumab (CaboNivo) improved objective response
rate (ORR), progression-free survival (PFS), and overall survival (OS) over sunitinib in a …
rate (ORR), progression-free survival (PFS), and overall survival (OS) over sunitinib in a …
[HTML][HTML] Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era
NJ Shah, SD Sura, R Shinde, J Shi, PK Singhal… - European Urology Open …, 2023 - Elsevier
Background Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on real-…
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on real-…
Clinical characterization of colitis arising from anti-PD-1 based therapy
DY Wang, MJ Mooradian, DW Kim, NJ Shah… - …, 2019 - Taylor & Francis
Colitis is a frequent, clinically-significant immune-related adverse event caused by anti-programmed
death-1 (PD-1). The clinical features, timing, and management of colitis with anti-PD…
death-1 (PD-1). The clinical features, timing, and management of colitis with anti-PD…